Bristol Myers Squibb, Amgen and Pfizer approach steepest patent cliffs among large drugmakers

Retrieved on: 2021-12-29 15:58:23

Tags for this article:

Click the tags to see associated articles and topics

Bristol Myers Squibb, Amgen and Pfizer approach steepest patent cliffs among large drugmakers. View article details on hiswai:

Excerpt

Biopharma companies are constantly combating patent expirations. But Bristol Myers Squibb, Amgen and Pfizer in particular will be the most ...

Article found on: www.fiercepharma.com